LRRK2 and Parkinson disease: The dominant gain-of-function mutation in LRRK2 is challenging for the treatment of parkinsonism by gene silencing or gene disruption strategies because LRRK2 plays pivotal roles in many regulatory pathways, including the immune system [11, 12].